Structural and Functional Characterization of the Enantiomers of the Antischistosomal Drug Oxamniquine.
For over two decades, a racemic mixture of oxamniquine (OXA) was administered to patients infected by Schistosoma mansoni, but whether one or both enantiomers exert antischistosomal activity was unknown. Recently, a ~30 kDa S. mansoni sulfotransferase (SmSULT) was identified as the target of OXA act...
Main Authors: | Alexander B Taylor, Livia Pica-Mattoccia, Chiara M Polcaro, Enrica Donati, Xiaohang Cao, Annalisa Basso, Alessandra Guidi, Anastasia R Rugel, Stephen P Holloway, Timothy J C Anderson, P John Hart, Donato Cioli, Philip T LoVerde |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS Neglected Tropical Diseases |
Online Access: | http://europepmc.org/articles/PMC4618941?pdf=render |
Similar Items
-
Resistance of schistosomes to hycanthone and oxamniquine
by: Donato Cioli, et al.
Published: (1989-01-01) -
The schistosome enzyme that activates oxamniquine has the characteristics of a sulfotransferase
by: Livia Pica-Mattoccia, et al.
Published: (2006-10-01) -
Why does oxamniquine kill Schistosoma mansoni and not S. haematobium and S. japonicum?
by: Anastasia R. Rugel, et al.
Published: (2020-08-01) -
The significance of variation in the susceptibility of Schistosoma mansoni to the antischistosomal drug oxamniquine
by: G. K. Kinoti
Published: (1987-01-01) -
An iterative process produces oxamniquine derivatives that kill the major species of schistosomes infecting humans.
by: Meghan A Guzman, et al.
Published: (2020-08-01)